Open Access
Numéro
Ann Toxicol Anal
Volume 22, Numéro 4, 2010
Page(s) 201 - 206
DOI https://doi.org/10.1051/ata/2011004
Publié en ligne 15 février 2011
  1. Verstraete A. Oral fluid testing for drivers under the influence of drugs: history, recent progress and remaining challenges. Forensic Sci Int. 2005; 150(1): 43-50. [Google Scholar]
  2. Samyn N, De Boeck G, Verstraete A. The use of oral fluid and sweat wipes for the detection of drugs of abuse in drivers. J Forensic Sci. 2002; 47(1): 380-387. [Google Scholar]
  3. Molina DK, Dimaio VJ. The reliability of immunoassay for determining the presence of opiates in the forensic setting. Am J Forensic Med Pathol. 2005; 26(4): 303-304. [CrossRef] [PubMed] [Google Scholar]
  4. Manchikanti L et al. Does random urine drug testing reduce illicit drug use in chronic pain patients receiving opioids? Pain Physician. 2006; 9(2): 123-129. [PubMed] [Google Scholar]
  5. Peel H, Perrigo B. Detection of cannabinoids in blood using EMIT. J Anal Toxicol. 1981; 5(4): 165-167. [PubMed] [Google Scholar]
  6. Phillis W, Ota K, Wade N. Tandem massspectrometry (MS/MS) utilizing electron impact ionization and multiple reaction monitoring for the rapid, sensitive and specific identification and quantitation of morphine in whole blood. J Anal Toxicol. 1989; 13: 268-273. [PubMed] [Google Scholar]
  7. Slightom E. The analysis of drugs in blood, bile and tissue with an indirect homogeneous enzyme immunoassay. J Forensic Sci. 1978; 23: 292-303. [PubMed] [Google Scholar]
  8. Bogusz M, Aderjan R, Schmitt G, Nadler E, Neurither B. The determination of drugs of abuse in whole blood by means of FPIA and EMIT d.a.u. immunoassays - A comparative study. Forensic Sci Int. 1990; 48: 27-37. [CrossRef] [PubMed] [Google Scholar]
  9. Moller M, Kraemer T. Drugs of abuse monitoring in blood for control of driving under the influence of drugs. Ther Drug Monit. 2002; 24(2): 210-221. [CrossRef] [PubMed] [Google Scholar]
  10. Apollonio LG, Whittall IR, Pianca DJ, Kyd JM, Maher WA. Matrix effect and cross-reactivity of select amphetamine-type substances, designer analogues, and putrefactive amines using the Bio-Quant direct ELISA presumptive assays for am phetamine and methamphetamine. J Anal Toxicol. 2007; 31: 208-213. [PubMed] [Google Scholar]
  11. Got P, Baud F, Sandouk P, Diamant-Berger U, Scherrmann J. Morphine disposition in opiatee intoxicated patients: relevance of nonspecific opiate inmunoassays. J Anal Toxicol. 1994; 18: 189-194. [PubMed] [Google Scholar]
  12. Moore K, Werner C, Zannelli R, Levine B, Smith M. Screening postmortem blood and tissues for nine cases of drugs of abuse using automated microplate inmunoassay. Forensic Sci Int. 1999; 106: 93-102. [CrossRef] [PubMed] [Google Scholar]
  13. Jolley M et al. Fluorescence polarization immunoassay III. An automated system for therapeutic drug determination. Clin Chem. 1981; 27: 1575-1579. [PubMed] [Google Scholar]
  14. Mc Gowan M et al. Therapeutic drug monitoring assays for the Abbot random/continuous access immunoassay analyzer. Clin Chem. 1992; 38: 1015. [Google Scholar]
  15. Keller T, Scheneider A, Dirnhofer R, Jungo R, Meyer W. Fluorescence polarization inmunoassay for the detection of drugs of abuse in human whole blood. Med Sci Law. 2000; 40(3): 258-262. [PubMed] [Google Scholar]
  16. Celinski R, Kulikowska J, Albert M, Sybirska H. Analitical problems in examination of small amounts of blood samples taken from law offenders. Arch Med Sadowej Kryminol. 2002; 52(3): 229-239. [PubMed] [Google Scholar]
  17. Hino Y, Ojanperä I, Rasanen I, Vuori E. Performance of immunoassays in screening for opiates cannabinoids and amphetamines in postmortem blood. Forensic Sci Int. 2003; 131(2-3): 148-155. [CrossRef] [PubMed] [Google Scholar]
  18. Kroener L, Musshoff F, Madea B. Evaluation of immunochemical drug screening of whole blood samples. A retrospective optimization of cuttoff levels after confirmation – analysis on GC-Ms and HPLC-DAD. J Anal Toxicol. 2003; 27(4): 205-212. [CrossRef] [PubMed] [Google Scholar]
  19. Spielher V, Isenschmid D, Matthews P, Kemp P, Kuplec T. Performance of a microtiter plate for screening of post-mortem blood for cocaine and metabolites. J Anal Toxicol. 2003; 27(8): 587-591. [PubMed] [Google Scholar]
  20. Diosi D, Harvey D. Analysis of whole blood for drugs of abuse using EMIT d.a.u. reagents in a Monarch 1000 chemistry analyzer. J Anal Toxicol. 1993; 17(3): 133-137. [PubMed] [Google Scholar]
  21. Domke I, Cremer P, Huchtemann M. Therapeutic drug monitoring on Cobas Integra 400-evaluation results. Clim Lab. 2000; 46(9-10): 509-515. [Google Scholar]
  22. Maier R, Erkens M, Hoenen H, Bogusz M. The screening for common drugs of abuse in whole blood by means of EMIT-ETS and FPIA-ADx urine immunoassays. Int J Legal Med. 1992; 105: 115-119. [CrossRef] [PubMed] [Google Scholar]
  23. Toennes S, Kauert G. Importance of vacutainer selection in forensic toxicological analysis of drugs of abuse. J Anal Toxicol. 2001; 25(5): 339-343. [PubMed] [Google Scholar]
  24. Hawks R. Analytical methodology. In: Chiang C, Hawks R (editors). Urine Testing for Drugs of Abuse: National Institute on Drug Abuse (NIDA). Research monograph 73. Rockville, MD: Department of Health and Human Services 1986: 35-38. [Google Scholar]
  25. Moeller M, Steinmeyer S, Kraemer T. Determination of drugs of abuse in blood. J Chromatogr B. 1998; 713(1): 91-109. [CrossRef] [Google Scholar]